Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 69, Issue 10, Pages 1761-1767Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-013-1541-5
Keywords
Preladenant; Adenosine A(2A) receptor antagonist; Thorough QT/QTc study; Parkinson's disease
Categories
Funding
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA
Ask authors/readers for more resources
Preladenant is an orally administered adenosine(2A) (A(2A)) receptor antagonist in phase III development for Parkinson's disease treatment. This thorough QT/QTc study evaluated its potential effects on cardiac repolarization. This was a randomized, double-blind, positive- and placebo-controlled, four-period crossover study performed under steady-state exposure of clinical and supratherapeutic doses of preladenant (10 mg BID and 100 mg BID, respectively, for 5 days), moxifloxacin (400 mg on day 5), or placebo in 60 healthy adult volunteers. The potential effect on QTcF was measured by the largest upper bound of 95 % one-sided CIs for the mean changes from time-matched baseline ECG recordings compared with placebo. Plasma preladenant concentrations were also determined on day 5. The QTcF difference for moxifloxacin compared with placebo exceeded 5 ms from 1 to 12 h postdose, establishing assay sensitivity. The QTcF interval was similar between the preladenant and placebo treatment groups: the upper bound of the 95 % one-sided CI for the mean difference in QTcF between preladenant and placebo was less than 10 ms at all time points for the supratherapeutic treatment group (1.3 to 5.7 ms, mean difference: -1.3 to 2.7 ms) and the therapeutic treatment group (0.4 to 4.3 ms, mean difference: -2.1 to 1.5 ms), substantially below the threshold of regulatory concern. The supratherapeutic dose (100 mg BID) provided a C-max margin of 6.1-fold and AUC margin of 6.9-fold, respectively, compared with 10 mg BID. At clinical and supratherapeutic doses, preladenant is not associated with QTc prolongation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available